SEARCH

SEARCH BY CITATION

References

  • BCSH Blood Transfusion Task Force (1996) Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine, 6, 261271.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Fladrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1989) The French–American–British (FAB) proposal for the classification of chronic (mature) B and T lymphoid leukaemias. Journal of Clinical Pathology, 42, 567584.
  • Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Boivin, P., Lesty, C., Duault, M., Monconduit, M., Belabbes, S. & Gremy, F. (1981) A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer, 48, 198206.
  • Boogaerts, M.A., Van Hoof, A., Catovsky, D., Kovacs, M., Montillo, M., Zinzani, P.L., Binet, J.L., Feremans, W., Marcus, R., Bosch, F., Verhoef, G. & Klein, M. (2001) Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 42524258.
  • Bosanquet, A.G., Johnson, S.A. & Richards, S.M. (1999) Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. British Journal of Haematology, 106, 7177.
  • Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., Colomor, D., Cobo, F., Esteve, J., Altes, A., Besalduch, J., Ribera, J. & Montserrat, E. (2002) Fludarabine, cyclophosphanide and mitoxauthrone in the treatment of resistent or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 119, 976984.
  • Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H. & Heerema, N.A. (2003a) Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Research, 63, 3638.
  • Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003b) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 614.
  • Byrd, J.C., Peterson, B., Piro, L., Saven, A., Vardiman, I.W., Larson, R.A. & Schiffer, C. (2003c) A phase II study of cladribine treatment for fludarabine refractory B-cell chronic lymphocytic leukemia: results from CALGB study 9211. Leukemia, 17, 323327.
  • Castelli, R., Vismara, A., Pavia, G., Dagani, R. & Porro, T. (2002) Relapsing pure red cell aplasisa associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Annali Italiani de Medicini Interna, 17, 4750.
  • Catovsky, D., Fooks, J. & Richards, S. (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. British Journal of Haematology, 72, 141149.
  • Catovsky, D., Richards, S., Fooks, J. & Hamblin, T. (1991) CLL trials in the United Kingdom. The Medical Research Council CLL Trials 1,2,3. Leukemia and Lymphoma, (Suppl.), 105107.
  • Chapel, H.M. & Bunch, C. (1987) Mechanisms of infection in chronic lymphocytic leukemia. Seminars in Hematology, 24, 291296.
  • Chapel, H., Dicato, M., Gamm, H., Brennan, V., Ries, F., Bunch, C. & Lee, M. (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. British Journal of Haematology, 88, 209212.
  • Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 49904997.
  • Chisesi, T., Capnist, G. & Dal Fior, S. (1991) Splenic irradiation in chronic lymphocytic leukemia. European Journal of Haematology, 46, 202204.
  • Christensen, B.E., Hansen, M.M. & Videbaek, A. (1977) Splenectomy in chronic lymphocytic leukaemia. Scandanavian Journal of Haematology, 18, 279287.
  • CLL Trialists’ Collaborative Group (1999) Chemotheraputic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. CLL Trialists’ Collaborative Group. Journal of National Cancer Institute, 91, 861868.
  • Cortes, J., O'Brien, S., Loscertales, J., Kantarjian, H., Giles, F., Thomas, D., Koller, C. & Keating, M. (2001) Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer, 92, 20162022.
  • Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. & Montserrat, E. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine, 348, 17641775.
  • Cusack, Jr, J.C., Seymour, J.F., Lerner, S., Keating, M.J. & Pollock, R.E. (1997) Role of splenectomy in chronic lymphocytic leukemia. Journal of American College of Surgery, 185, 237243.
  • Dabaja, B.S., O'Brien, S.M., Kantarjian, H.M., Cortes, J.E., Thomas, D.A., Albitar, M., Schlette, E.S., Faderl, S., Sarris, A., Keating, M.J. & Giles, F.J. (2001) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leukemia and Lymphoma, 42, 329337.
  • Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 18401847.
  • Del Poeta, G., Maurillo, L., Venditti, A., Buccisano, F., Epiceno, A.M., Capelli, G., Tamburini, A., Suppo, G., Battaglia, A., Del Principe, M.I., Del Moro, B., Masi, M. & Amadori, S. (2001) Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood, 98, 26332639.
  • Delpero, J.R., Houvenaeghel, G., Gastaut, J.A., Orsoni, P., Blache, J.L., Guerinel, G. & Carcassonne, Y. (1990) Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-Hodgkin's lymphoma. British Journal of Surgery, 77, 443449.
  • Di Raimondo, F., Giustolisi, R., Lerner, S., Cacciola, E., O'Brien, S., Kantarjian, H. & Keating, M.J. (2001) Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Annals of Oncology, 12, 621625.
  • Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., Binet, J.L. & Travade, P. (1998) Chlorambucil in indolent chronic lymphocytic leukemia. French Co-operative Group on Chronic Lymphocytic Leukemia. New England Journal of Medicine, 338, 15061514.
  • Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P., Poustka, A., Hunstein, W. & Lichter, P. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 15801588.
  • Dohner, H., Stilgenbauer, S., James, M.R., Benner, A., Weilgum, T. & Bentz, M. (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukaemia characterised by extensive nodal involvement and inferior prognosis. Blood, 89, 26162522.
  • Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 19101916.
  • Dreger, P. & Montserrat, E. (2002) Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia, 16, 985992.
  • Dreger, P., van Biezen, A., Brand, R., Esteve, J., Gratwohl, A., Kimby, E., Michallet, M., Milligan, D.W. & Niederwieser, D. (2000a) Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EMBT experience. Blood, 96(Suppl. 1), 482a.
  • Dreger, P., von Neuhoff, N., Sonnen, R., Kuse, R., Seyfarth, B., Glass, B. & Schmitz, N. (2000b) Feasibility and efficacy of autologous stem cell transplantation for poor risk CLL. Blood, 96(Suppl. 1), 483a.
  • Dreger, P., van Biezen, A., Brand, R., Hansz, J., Corradini, P., Finke, J., Lambertenghi-Deliliers, G., Russell, N., Michallet, M. & Niederwieser, D. (2001). Allogenic stem cell transplantation (SCT) for chronic lymphocytic leukaemia using intensisty-reduced conditioning. An EMBT survey. Blood, 98, 743a.
  • Dreger, P., Stilgenbauer, S., Benner, A., Ritgen, M., Schmitz, N. & Dohner, H. (2002) High-dose therapy with autologous stem cell transplantation (ASCT) prolongs survival of patients with chronic lymphocytic leukemia (CLL): a matched-pair analysis. Blood, 100(Suppl. 1), 217a.
  • Dreger, P., Brand, R., Hansz, J., Milligan, D., Corradini, P., Finke, J., Deliliers, G., Martino, R., Russell, N., Van Biezen, A., Michallet, M. & Niederwieser, D. (2003) Treatment related mortality and graft versus leukemia effect after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity reduced conditioning. Leukemia, 17, 841848.
  • Durig, J., Nascher, M., Schmucker, U., Renzing-Kohler, K., Huttmann, A. & Duhrsen, U. (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia, 16, 3035.
  • Eichhorst, B., Busch, R., Stauch, M., Kneba, M., Ritgen, M., Soling, U., Burkhard, O., Bergmann, M., Wendtner, M., Hiddermann, W., Emmerich, B. & Hallek, M. (2003a) Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil: interim analysis of a phase 111 study of the German CLL study group. Blood, 102(Suppl. 1), 109a.
  • Eichhorst, B., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Soling, U., Siehl, S., Steinbrecher, C., Jager, U., Bergmann, M., Wendtner, M., Hiddermann, W., Emmerich, B. & Hallek, M. (2003b) Fludarabine plus cyclophosphamide induces higher remission rates and longer progression free survival than fludarabine alone in first line therapy of advanced chronic lymphocytic leukemia: results of a phase 111 study of the German CLL study group. Blood, 102(Suppl. 1), 72a.
  • Esteve, J., Montserrat, E., Dreger, P., Meloni, G., Pavletic, S., Catovsky, D., Dearden, D., Scime, C., Sutton, L., Michallet, M., Desablens, B., Kimby, E., Coiffier, B., Brunet, S., Sanz, M.A., Besalduch, J., Cabellero, D., Juliusson, G., Conde, E., Del Potro, E. & Schmitz, N. (2001) Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogenic transplants. Blood, 98(Suppl. 1), 482a.
  • Esteve, J., Vilamor, N., Colomer, D. & Montserrat, E. (2002) Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood, 99, 18731874.
  • Ezdinli, E., Stutzman, L., William August, C. & Firat, D. (1969) Corticosteriod therapy for lymphomas and chronic lymphocytic leukemia. Cancer, 23, 900909.
  • Faderl, S., Thomas, D.A., O'Brian, S., Giles, F., Koller, C.A., Beran, M., Williams, M., Garcia-Manero, G., Kantarjian, H.M. & Keating, M.J. (2001) An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD52- and CD20-positive chronic lymphoid disorders. Blood, 98(Suppl. 1), 365a.
  • Forsyth, P., Milligan, D. & Davies, F.E. (2000) High dose chemoradiotherapy with autologous stem cell rescue for patients with CLL is an effective and safe means of inducing molecular responses: an MRC pilot study. Blood, 96(Suppl. 1), 843a.
  • French Co-operative Group on Chronic Lymphocytic Leukaemia (1990a) Natural history of stage A chronic lymphocytic leukaemia untreated patients. British Journal of Haematology, 76, 4557.
  • French Co-operative Group on Chronic Lymphocytic Leukaemia (1990b) A randomized clinical trial of chlorambucil versus COP in stage A chronic lymphocytic leukaemia. French Co-operative Group on Chronic Lymphocytic Leukaemia. Blood, 75, 14221425.
  • French Co-operative Group on CLL, Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet, 347, 14321438.
  • Gale, R.P. & Montserrat, E. (1993) Intensive therapy of chronic lymphocytic leukaemia. Bailliere's Clinical Haematology, 6, 879885.
  • Galton, D., Wiltshire, E., Szur, J. & Dacie, J. (1961) The use of chlorambucil and steriods in the treatment of chronic lymphocytic leukaemia. British Journal of Haematology, 7, 7398.
  • Garcia-Manero, G., O'Brien, S., Cortes, J., Faderl, S., Giles, F., Albitar, M., Lerner, S., Kantarjian, H. & Keating, M. (2001) Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL). Blood, 98(Suppl. 1), 633a.
  • Ghazal, H. (2002) Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood, 99, 10921094.
  • Ghia, P., Guida, G., Stella, S., Gottardi, D., Guena, M., Strola, G., Scielzo, C. & Caligaris-Cappio, F. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood, 101, 12621269.
  • Giles, F.J., O'Brien, S.M. & Keating, M.J. (1998) Chronic lymphocytic leukemia in (Richter's) transformation. Seminars in Oncology, 25, 117125.
  • Giles, F.J., O'Brien, S.M., Santini, V., Gandhi, V., Plunkett, W., Seymour, J.F., Robertson, L.E., Kantarjian, H.M. & Keating, M.J. (1999) Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leukemia and Lymphoma, 36, 5765.
  • Girinsky, T., Guillot-Vals, D., Koscielny, S., Cosset, J.M., Ganem, G., Carde, P., Monhonval, M., Pereira, R., Bosq, J., Ribrag, V., Vantelon, J.M. & Munck, J.N. (2001) A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. International Journal of Radiation Oncology, Biology, Physics, 51, 148155.
  • Grever, M.R., Kopecky, K.J., Coltman, C.A., Files, J.C., Greenberg, B.R., Hutton, J.J., Talley, R., Von Hoff, D.D. & Balcerzak, S.P. (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukaemia. Nouvelle Revue Francaise d'Hematologie, 30, 457459.
  • Gribabis, D.A., Panayiotidis, P., Boussiotis, V.A., Hannoun, C. & Pangalis, G.A. (1994) Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica, 91, 115118.
  • Gribben, J.C., Neuberg, D., Soiffer, R.J., Fischer, D.C., Schlossman, R., Alyea, E.P., Kuhlman, C., Ritz, J. & Nadler, L.M. (1998) Autologous versus allogenic bone marrow transplantation for patients with poor prognosis CLL. Blood, 92(Suppl.), 322a.
  • Griffiths, H., Brennan, V., Lea, J., Bunch, C., Lee, M. & Chapel, H. (1989) Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood, 73, 366368.
  • Gupta, N.K., Patel, D., Kavuru, S., Janson, D., Hoffman, M., Ramadoss, U., Ahmed, S. & Rai, K. (2001) Rituximab, cyclophosphamide and decadron (RCD) is effective in previously treated advanced chronic lymphocytic leukaemia (CLL). Journal of Clinical Oncology, 20, page 284a (abstract no. 1133).
  • Gupta, N.K., Kavuru, S., Patel, D., Janson, D., Driscoll, N. & Ahmed, S. (2002) Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 10, 20922095.
  • Hainsworth, J., Litchy, S., Barton, J., Houston, G., Hermann, F., Bradof, J. & Greco, F. (2003) Single agent rituximab as first line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 17461751.
  • Hallek, M., Langenmayer, I., Nerl, C., Knauf, W., Dietzfelbinger, H., Adorf, D., Ostwald, M., Busch, R., Kuhn-Hallek, I., Thiel, E. & Emmerich, B. (1999) Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood, 93, 17321737.
  • Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G., Emmerich, B. & the German Chronic Lymphocytic Leukaemia Study Group (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114, 342348.
  • Hamblin, T. (2001) Autoimmune Disease and Its Management in Chronic Lymphocytic Leukemia. In: Chronic Lymphoid Leukemias (ed. by B.D. Cheson), pp. 435458. Marcel Dekker, New York.
  • Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 18481854.
  • Hamblin, T.J., Orchard, J.A., Ibbotson, R.E., Davis, Z., Thomas, P.W., Stevenson, F.K. & Oscier, D.G. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 99, 10231029.
  • Han, T., Ezdinli, E.Z., Shimaoka, K. & Desai, D.V. (1973) Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer, 31, 502508.
  • Hegde, U.P., Wyndham, H.W., White, T. & Cheson, B.D. (2002) Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood, 100, 22602262.
  • Hensel, M., Kornacker, M., Yammeni, S., Egerer, G. & Ho, A. (2003) Disease activity and pretreatment rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 122, 600606.
  • Horowitz, M.M., Montserrat, E., Sobocinski, K., Giralt, S., Khouri, I.F. & Schmitz, N. (2000) Haemopoietic stem cell transplantation for chronic lymphocytic leukaemia. Blood, 96(Suppl. 1), 522a.
  • Houlston, R., Catovsky, D. & Yuille, M. (2002) Genetic susceptibility to chronic lymphocytic leukemia. Leukemia, 16, 10081014.
  • Ibrahim, S., Keating, M., Do, K.A., O'Brien, S., Huh, Y.O., Jilani, I., Lerner, S., Kantarjian, H.M. & Albitar, M. (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood, 98, 181186.
  • Jaksic, B. & Brugiatelli, M. (1988) High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL–IGCI CLL-01 trial. Nouvelle Review Francais d'Hematologie, 30, 437442.
  • Jaksic, B. & Vitale, B. (1981) Total tumour mass score (TTM): a new parameter in chronic lymphocyte leukaemia. British Journal of Haematology, 49, 405413.
  • Jaksic, B., Brugiatelli, M., Krc, I., Losonczi, H., Holowiecki, J., Planinc-Peraica, A., Kusec, R., Morabito, F., Iacopino, P. & Lutz, D. (1997) High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer, 79, 21072114.
  • Johnson, S., Smith, A.G., Loffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxirubicin, and prednisilone (CAP) for the treatment of advanced-stage chronic lymphocytic leukaemia. The French Co-operative Group on CLL. Lancet, 347, 14321438.
  • Juliusson, G. & Liliemark, J. (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukaemia: response predicted by rapid decrease of blood lymphocyte count. Journal of Clinical Oncology, 11, 679689.
  • Juliusson, G. & Liliemark, J. (1994) Retreatment of chronic lymphocytic leukaemia with 2-chlorodeoyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leukemia and Lymphoma, 13, 7580.
  • Juliusson, G. & Liliemark, J. (1996) Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukaemia. Annals of Oncology, 7, 373379.
  • Juliusson, G., Oscier, D.G., Fitchett, M., Ross, F.M., Stockdill, G., Mackie, M.J., Parker, A.C., Castoldi, G.L., Cuneo, A., Knuutila, S., Elonen, E. & Gahrton, G. (1990) Prognostic subgroups in B-cell chronic lymphocytic leukaemia defined by specific chromosomal abnormalities. New England Journal of Medicine, 323, 720724.
  • Juliusson, G., Elmhorn-Rosenborg, A. & Liliemark, J. (1992) Response to chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine, 327, 10561061.
  • Juliusson, G., Christiansen, I., Hansen, M.M., Johnson, S., Kimby, E., Elmhorn-Rosenborg, A. & Liliemark, J. (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. Journal of Clinical Oncology, 14, 21602166.
  • Jurlander, J., Geisler, C.H. & Hansen, M.M. (1994) Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. European Journal of Hematology, 53, 114118.
  • Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J. & McCredie, K.B. (1988) Fludarabine therapy in chronic lymphocytic leukaemia (CLL). Nouvelle Revue Francaise d'Hematologie, 30, 461466.
  • Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McCredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukaemia. Blood, 74, 1925.
  • Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. & Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 11651171.
  • Keating, M.J., Smith, T.L., Lerner, S., O'Brien, S., Robertson, L.E., Kantarjian, H. & Freireich, E.J. (2000) Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukaemia. Leukemia and Lymphoma, 37, 7185.
  • Keating, M.J., Manshouri, T., O'Brien, S., Wierda, W., Kantarjian, H., Washington, L., Lerner, S. & Abitar, M. (2002a) A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukaemia (CLL). Blood, 100(Part 1), 205a.
  • Keating, M.J., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S. & Kantarjian, H. (2002b) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukaemia. Leukemia and Lymphoma, 43, 17551762.
  • Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002c) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 35543561.
  • Kennedy, B., Rawstron, A., Haynes, A., Fegan, C., Leach, M., Tighe, J., Rassam, S., Hale, G., Morgan, G. & Hillmen, P. (2001) Eradication of detectable minimal residual disease with Campath-1H therapy results in prolonged survival in patients with refractory B-CLL. Blood, 98(Suppl. 1), 365a.
  • Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G. & Hillmen, P. (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 99, 22452247.
  • Knauf, W.U., Ehlers, B., Mohr, B., Thiel, E., Langenmayer, I., Hallek, M., Emmerich, B., Adorf, D., Nerl, C. & Zwingers, T. (1997) Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood, 89, 42414242.
  • Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 14101416.
  • Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 23192325.
  • Lin, K., Sherrington, P.D., Dennis, M., Matrai, Z., Cawley, J.C. & Pettitt, A.R. (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood, 100, 14041409.
  • Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P.A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768773.
  • Mauro, F.R., Foa, R., Giannarelli, D., Cordone, I., Crescenzi, S., Pescarmona, E., Sala, R., Cerretti, R. & Mandelli, F. (1999) Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood, 94, 448454.
  • Mauro, F.R., Foa, R., Cerretti, R., Giannarelli, D., Coluzzi, S., Mandelli, F. & Girelli, G. (2000) Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 95, 27862792.
  • Michallet, M., Carreras, E., Cornelissen, J.J., Dreger, P., Einsele, H., Gratwohl, A., Kimby, E., Niederwieser, D. & Apperley, J. (1999) Allotransplants and autotransplants in CLL (abstract). Bone Marrow Transplantation, 23, S53.
  • Michallet, M., Thiebaud, A., Dreger, P., Remes, K., Milpied, N., Santini, G., Hamon, M., Bjorkstrand, B., Kimby, E., Belhabri, A., Tanguy, M. & Apperley, J. (2000) Peripheral blood stem cell mobilisation and transplantation after fludarabine therapy in chronic lymphocytic leukaemia: a report of the EBMT CLL Subcommittee on behalf of the EBMT Chronic Leukaemia Working Party. British Journal of Haematology, 108, 595601.
  • Molica, S. (1994) Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leukemia and Lymphoma, 13, 203214.
  • Monteserrat, N., Vinolas, N., Reverter, J.C. & Rozman, C. (1988) Natural history of chronic lymphocytic leukaemia: on the progression and prognosis of early stages. Nouvelle Review Francais d'Hematologie, 30, 359361.
  • Montillo, M., Tedeschi, A., Cafro, A.M., Rossi, V., D'Avanzo, G., Pungolino, E., Cairoli, R., Oreste, P., Veronese, S., Brando, B. & Morra, E. (2002) Sequential subcutaneous administration of CAMPATH-1H as treatment of minimal residual disease in CLL patients responding to fludarabine (FAMP). Blood, 100(Suppl. 1), 805a.
  • Montillo, M., Tedeschi, A., O'Brien, S., DiRaimondo, F., Lerner, S., Ferrajoli, A., Morra, E. & Keating, M. (2003) Phase 11 study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer, 79, 114120.
  • Montserrat, E. & Rozman, C. (1993) Chronic lymphocytic leukaemia: prognostic factors and natural history. Bailliere's Clinical Haematology, 6, 849866.
  • Montserrat, E., Alcala, A., Parody, R., Domingo, A., Garcia-Conde, J., Bueno, J., Ferran, C., Sanz, M.A., Giralt, M. & Rubio, D. (1985) Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial, comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer, 56, 23692375.
  • Montserrat, E., Gomis, F., Vallespi, T., Rios, A., Romero, A., Soler, J., Alcala, A., Morey, M., Ferran, C., Diaz-Mediavilla, J., Flores, A., Woessner, S., Batille, J., Gonzales-Aza, C., Rovira, M., Reverter, J. & Rozman, C. (1991) Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood, 78, 15451551.
  • Montserrat, E., Lopez-Lorenzo, J.L., Manso, F., Martin, A., Prieto, E., Arias-Sampedro, J., Fernandez, M.N., Oyarzabal, F.J., Odriozola, J., Alcala, A., Garcia-Conde, J., Guardia, R. & Bosch, F. (1996) Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leukaemia and Lymphoma, 21, 467472.
  • Moreau, E.J., Matutes, E., A'Hern, R.P., Morilla, A.M., Morilla, R.M., Owusu-Ankomah, K.A., Seon, B.K. & Catovsky, D. (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology, 108, 378382.
  • Morrison, V.A. (2001) Infections in Patients with Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum and Theraputic Approaches. In: Chronic Lymphoid Leukemias (ed. by B.D.Cheson), pp. 505523. Marcel Dekker, New York.
  • Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., Shepherd, L., Larson, R.A. & Schiffer, C.A. (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Journal of Clinical Oncology, 20, 38783884.
  • Myint, H., Copplestone, J.A., Orchard, J., Craig, V., Curtis, D., Prentice, A.G., Hamon, M.D., Oscier, D.G. & Hamblin, T.J. (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 91, 341344.
  • Nabhan, C., Tallman, M.S. & Riley, M.B. (2001) Phase 1 study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukaemia. Blood, 98(Suppl. 1), 365a.
  • National Institute for Clinical Excellence (2001) Guidance on the use of fludarabine for B-cell lymphocytic leukaemia. Technology Appraisal Guidance 29. National Institute for Clinical Excellence, London.
  • Neal, Jr, T.F., Tefferi, A., Witzig, T.E., Su, J., Phyliky, R.L. & Nagorney, D.M. (1992) Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. American Journal of Medicine, 93, 435440.
  • O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, 82, 16951700.
  • O'Brien, S., Kantarjian, H., Beran, M., Koller, C., Talpaz, M., Lerner, S. & Keating, M.J. (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia, 11, 16311635.
  • O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 14141420.
  • O'Brien, S.M., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F.J., Wierda, W.G., Koller, C.A., Ferrajoli, A., Browning, M., Lerner, S., Abitar, M. & Keating, M.J. (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, 98, 26572663.
  • Orchard, J.A., Ibbotson, R.E., Davis, Z.A., Gardiner, A.C., Hamblin, T.J. & Oscier, D.G. (2004) Zap-70 evaluation by flow cytometry is a significant prognostic marker in B-CLL. Lancet, 363, 105111.
  • Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 11771184.
  • Osterborg, A., Fassas, A.S., Anagnostopoulos, A., Dyer, M.J., Catovsky, D. & Mellstedt, H. (1996) humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocyitic leukaemia. British Journal of Haematology, 93, 151153.
  • Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 15671574.
  • Pegourie, B., Sotto, J.J., Hollard, D., Michallet, M. & Sotto, M.F. (1987) Splenectomy during chronic lymphocytic leukemia. Cancer, 59, 16261630.
  • Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. & Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 31213127.
  • Perkins, J.G., Flynn, J.M., Howard, R.S. & Byrd, J.C. (2002) Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94, 20332039.
  • Pfitzner, T., Reiser, M., Barth, S., Borchmann, P., Schulz, H., Schinkothe, T., Oberhauser, F., Wessels, J., Tur, M., Diehl, V. & Engert, A. (2002) Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Annals of Hematology, 81, 258266.
  • Piro, L.D., Carrera, C.J., Beutler, E. & Carson, D.A. (1988) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood, 72, 10691073.
  • Rabinowe, S.N., Soiffer, R.J., Gribben, J.G., Daley, H., Freedman, A.S., Daley, J., Pesek, K., Neuberg, D., Pinkus, G. & Leavitt, P.R. (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood, 82, 13661376.
  • Rai, K.I., Sawitsky, A., Cronkite, E.P., Chanana, A., Levy, R. & Pasternak, B. (1975) Clinical staging of chronic lymphocytic leukaemia. Blood, 46, 219234.
  • Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 17501757.
  • Rai, K., Coutre, S., Rizzeri, D., Gribben, J., Flinn, I., Rabinowe, S. & Keating, M. (2001) Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood, 98(Suppl. 1), 365a.
  • Raphael, B., Andersen, J.W., Silber, R., Oken, M., Moore, D. & Bennett, J. (1991) Comparison of chlorambucil and prednisone versus cyclophosphamide, vicristine and prednisone as an initial treatment for chronic lymphocytic leukaemia: a long term follow up of an Eastern Co-operative Oncology Group randomised clinical trial. Journal of Clinical Oncology, 9, 770776.
  • Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 2935.
  • Rawstron, A.C., Yuille, M.R., Fuller, J., Cullen, M., Kennedy, B., Richards, S.J., Jack, A.S., Matutes, E., Catovsky, D., Hillmen, P. & Houlston, R.S. (2002) Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 100, 22892290.
  • Richter, M.N. (1928) Generalised reticular cell sarcoma of lymph nodes associated with lymphocytic leukemia. American Journal of Pathology, 4, 285292.
  • Ritgen, M., Dreger, P., Humpe, A., Stilgenbauer, S., Döhner, H. & Kneba, M. (2002). Quantitative PCR demonstrates effective graft versus host leukemia activity after allogeneic stem cell transplantation using reduced intensity conditioning in patients with chronic lymphocytic leukemia. Blood, 100(Suppl. 1), 854a.
  • Ritgen, M., Lange, A., Stilgenbauer, S., Dohner, H., Bretscher, C., Bosse, H., Stuhr, A., Kneba, M. & Dreger, P. (2003) Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood, 101, 20492053.
  • Robak, T. & Kasznicki, M. (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia, 16, 10151027.
  • Robak, T., Blonski, J.Z., Kasznicki, M., Blasinska-Morawiec, M., Krykowski, E., Dmoszynska, A., Mrugala-Spiewak, H., Skotnicki, A.B., Nowak, W., Konopka, L., Ceglarek, B., Maj, S., Dwilewicz-Trojaczek, J., Hellmann, A., Urasinski, I., Zdziarska, B., Kotlarek-Haus, S., Potoczek, S. & Grieb, P. (2000a) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 96, 27232729.
  • Robak, T., Blonski, J.Z., Kasznicki, M., Konopka, L., Ceglarek, B., Dmoszynska, A., Soroka-Wojtaszko, M., Skotnicki, A.B., Nowak, W., Dwilewicz-Trojaczek, J., Tomaszewska, A., Hellman, A., Lewandowski, K., Kuliczkowski, K., Potoczek, S., Zdziarska, B., Hansz, J., Kroll, R., Komarnicki, M., Holowiecki, J. & Grieb, P. (2000b) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – updated results of the multicentre study of 378 patients. British Journal of Haematology, 108, 357368.
  • Robertson, L.E., Pugh, W., O'Brien, S., Kantarjian, H., Hirsch-Ginsberg, C., Cork, A., McLaughlin, P., Cabanillas, F. & Keating, M.J. (1993) Richter's syndrome: a report on 39 patients. Journal of Clinical Oncology, 11, 19851989.
  • Ru, X. & Liebman, H. (2003) Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). British Journal of Haematology, 123, 278281.
  • Rummel, M.J., Kafer, G., Pfreundschuh, M., Jager, E., Reinhardt, U., Mitrou, P.S., Hoelzer, D. & Bergmann, L. (1999) Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German Multicentre phase II study. Annals of Oncology, 10, 183188.
  • Saven, A., Carrera, C.J., Carson, D.A., Beutler, E. & Piro, L.D. (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. Leukemia and Lymphoma, 5(Suppl.), 133138.
  • Saven, A., Lemon, R.H., Kosty, M., Beutler, E. & Piro, L.D. (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukaemia. Journal of Clinical Oncology, 14, 21602166.
  • Sawitsky, A., Rai, K.R., Glidewell, O. & Silver, R.T. (1979) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood, 50, 10491059.
  • Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.U., Aulitzky, W.E., Hensel, M., Herold, M., Huhn, D., Hallek, M., Diehl, V. & Engert, A. (2002) Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood, 100, 31153120.
  • Schwarzmeier, J.D., Shehata, M., Hilgarth, M., Marschitz, I., Louda, N., Hubmann, R. & Greil, R. (2002) The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. Leukemia and Lymphoma, 43, 549554.
  • Seymour, J.F., Cusack, J.D., Lerner, S.A., Pollock, R.E. & Keating, M.J. (1997) Case/control study of the role of splenectomy in chronic lymphocytic leukemia. Journal of Clinical Oncology, 15, 5260.
  • Sgambati, M.T., Linet, M.S. & Devesa, S.S. (2001) Chronic Lymphocytic Leukemia: Epidemiological, Familial, and Genetic Aspests. In: Chronic Lymphoid Leukemias (ed. by B.D.Cheson), pp. 3362. Marcel Dekker, New York.
  • Sinisalo, M., Aittoniemi, J., Oivanen, P., Kayhty, H., Olander, R.M. & Vilpo, J. (2001) Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 114, 107110.
  • Sinisalo, M., Aittoniemi, J., Kayhty, H. & Vilpo, J. (2003) Vaccination strategies against infections in chronic lymphocytic leukemia. Leukemia and Lymphoma, 44, 649652.
  • Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. & Cheson, B.D. (1997) Treatment of refractory chronic lymphocytic leukaemia with fludarabine phosphate via the Group C Protocol mechanism of the National Cancer Institute: five-year follow-up report. Journal of Clinical Oncology, 15, 458465.
  • Stilgenbauer, S. & Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. New England Journal of Medicine, 347, 452453.
  • Stilgenbauer, S., Neuhoff, N., Bullinger, L., Krober, A., Lichter, P., Dreger, P. & Dohner, H. (2000) Deletion 11q23 identifies B-CLL patients at high risk for molecular disease persistance after high dose therapy and autografting. Blood, 96(Suppl. 1), 715a.
  • Thornton, P.D., Matutes, E., Bosanquet, A.G., Lakhani, A.K., Grech, H., Ropner, J.E., Joshi, R., Mackie, P.H., Douglas, I.D., Bowcock, S.J. & Catovsky, D. (2003) High dose methyl prednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology, Oct 10, (E-pub ahead of print).
  • Tobin, G., Thurnberg, U., Johnson, A., Thorn, I., Soderberg, O., Hultdin, M., Botling, J., Enblad, G., Sallstrom, J., Sundstrom, C., Roos, G. & Rosenquist, R. (2002) Somatically mutated Ig VH3–21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, 99, 22622264.
  • Tournilhac, O., Cazin, B., Lepretre, S., Devine, M., Maloum, K., Delmer, A., Grosbois, B., Feugier, P., Maloisel, F., Villard, F., Villemagne, B., Bastit, D., Belhadj, K., Azar, N., Michallet, M., Manhes, G. & Travade, P. (2004). Impact of frontline fludarabine and cyclophosphamide treatment on peripheral blood stem cell mobilisation in B cell chronic lymphocytic leukemia. Blood, 103, 363–365.
  • Van Besien, K., Keralavarma, B., Devine, S. & Stock, W. (2001) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia, 15, 13171325.
  • Van Mook, W.N., Fickers, M.M. & Verschueren, T.A. (2001) Clinical and immunological evaluation of primary splenic irradiation in chronic lymphocytic leukemia: a study of 24 cases. Annals of Hematology, 80, 216223.
  • Weeks, J.C., Tierney, M.R. & Weinstein, M.C. (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New England Journal of Medicine, 325, 8186.
  • Weiss, R.B., Freiman, J., Kweder, S.L., Diehl, L.F. & Byrd, J.C. (1998) Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 16, 18851889.
  • Wierda, W., O'Brien, S., Fader, S., Ferrajoli, A., Lerner, S., Wang, X., Thomas, D., Garcia-Manero, G., Cortes, J., Kantarjian, H. & Keating, M. (2003) Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Blood, 102(Suppl. 1), 110a.
  • Wiestner, A., Rosenwald, A., Barry, T.S., Wright, G., Davis, E., Henrickson, S., Zhao, H., Ibbotson, R., Orchard, J., Davis, Z., Stetler-Stevenson, M., Raffeld, M., Arthur, D.C., Marti, G., Wilson, W.H., Hamblin, T., Oscier, D. & Staudt, L. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood, 101, 49444951.
  • Yuille, M.R., Houlston, R.S. & Catovsky, D. (1998) Anticipation in familial chronic lymphocytic leukaemia. Leukemia, 12, 16961698.
  • Zittoun, R., De Witte, T., et al , (1999) A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. Hematology and Cell Therapy, 41, 127136.